The purpose of this document is to highlight processes for minimizing treatment delays for patients with acute myeloid leukemia (AML) on venetoclax and hypomethylating agent (HMA) therapy including optimization of venetoclax initiation and continued patient management.
2026 Oncology Institute
August 12, 2026 | 12:00 PM EST